Filing Flows

Filing Flows › Health Care › Cryo Cell International (CCEL)

Cryo Cell International (CCEL) earnings and revenue breakdown

Latest: Q3 FY26 · 10-Q filed Oct 9, 2026 · Cryo Cell International (CCEL) Q3 FY26 earnings results →

Q3 FY26 Revenue up 0% year over year to $7.8M · 16¢ of every $1 of revenue kept as net profit · operating margin 28.0%

Cryo Cell International made $7.8M in Q3 FY26 (0% Y/Y): Processing and Storage Fees $7.7M, Public Banking $135K, Product $39K. Operating margin 28.0%, net earnings $1.3M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Oct 9, 2026.

Revenue$7.8M
Year over year0%
Operating margin28.0%
Net earnings$1.3M
Operating cash flow$1.1M

Drawing the Sankey…

Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF

What changed this quarter

Revenue was $7.8M in Q3 FY26, roughly flat year over year and up 1% from the previous quarter. Processing and Storage Fees was the largest line at 98% of revenue. Processing and Storage Fees lost $171K year over year (down 2%), 13373% of the total change.

Operating profit was $2.2M, a 28.0% margin (up 3.8 points year over year). Total costs fell 5% while revenue was flat. Net earnings were $1.3M, up 70% year over year. The effective tax rate was 30.4%.

Operating cash flow was $1.1M (down 55% year over year), 90% of net earnings. Non-cash charges added back $241K of depreciation and amortization and $93K of share-based compensation. Working capital and other items used $462K. Capital expenditures of $102K left free cash flow of $1.0M.

Quarterly history

Cryo Cell International revenue by quarterCryo Cell International revenue by quarter$8.0MQ1 FY25$7.9MQ2 FY25$7.8MQ3 FY25$7.8MQ4 FY25$7.7MQ1 FY26$7.8MQ2 FY26$7.8MQ3 FY26
Cryo Cell International net earnings by quarterCryo Cell International net earnings by quarter$283KQ1 FY25$356KQ2 FY25$749KQ3 FY25−$3.8MQ4 FY25$47KQ1 FY26$555KQ2 FY26$1.3MQ3 FY26
QuarterFormFiledRevenueY/YOp. marginNet earningsOp. cash flow
Q3 FY2610-QOct 9, 2026$7.8M0%28.0%$1.3M$1.1M
Q2 FY2610-QJul 15, 2026$7.8M-2%15.4%$555K$1.8M
Q1 FY2610-QApr 14, 2026$7.7M-4%10.0%$47K$652K
Q4 FY2510-KFeb 27, 2026$7.8M-2%-50.6%−$3.8M$1.3M
Q3 FY2510-QOct 15, 2025$7.8M-3%24.3%$749K$2.5M
Q2 FY2510-QJul 15, 2025$7.9M-1%18.8%$356K$707K
Q1 FY2510-QApr 14, 2025$8.0M+2%13.3%$283K$954K

Charts

Cryo Cell International: revenue growth, year over year and quarter over quarterCryo Cell International: revenue growth, year over year and quarter over quarterY/YQ/Q+2%Q1 FY25-1%-1%Q2 FY25-3%-1%Q3 FY25-2%+0%Q4 FY25-4%-2%Q1 FY26-2%+1%Q2 FY260%+1%Q3 FY26
Latest (Q3 FY26): Y/Y 0%, Q/Q +1%.
Cryo Cell International: where the cash came from (+) and went (−), TTM to Q3 FY26Cryo Cell International: where the cash came from (+) and went (−), TTM to Q3 FY26Operating cash flow$4.9MNet borrowing (+) / repaid (−)−$3.4MCash drawn (+) / kept (−)−$1.2MCapital spending−$269KOther investing−$147KShares issued$23K
From the cash-flow statement as filed (SEC XBRL). Cash is fungible: the bars do not say which dollar paid for what.
Cryo Cell International: profit against cash, quarter by quarterCryo Cell International: profit against cash, quarter by quarterNet incomeOperating cash flow−$1.9M$2.2MQ4 FY24$283K$954KQ1 FY25$356K$707KQ2 FY25$749K$2.5MQ3 FY25−$3.8M$1.3MQ4 FY25$47K$652KQ1 FY26$555K$1.8MQ2 FY26$1.3M$1.1MQ3 FY26
Latest (Q3 FY26): Net income $1.3M, Operating cash flow $1.1M.
Cryo Cell International: diluted shares by fiscal yearCryo Cell International: diluted shares by fiscal year8MFY208MFY218MFY228MFY238MFY248MFY25
-0.9% since FY20: buybacks shrank the count.
Cryo Cell International: long-term debt falling due (FY25)Cryo Cell International: long-term debt falling due (FY25)$184K2026$202K2027$214K2028$227K2029$242K2030$7.4MLater
Cash $319K, short-term investments $3.0M, long-term debt $8.4M at 2025-11-30.
Cryo Cell International in its industry: growth against margin (10 companies, SIC 8090)Cryo Cell International in its industry: growth against margin (10 companies, SIC 8090)revenue growth, year over year →↑ operating marginmedian +5%median 9%DVAAGLPGNYSHCVMDPARKMRAIPFHOMGRXCCEL (0%, 28%)
Services-Misc Health & Allied Services, NEC; dot size is quarterly revenue; dashed lines are the industry's medians.

Interactive views

The same charts as the app — open one to draw it.

💵Where each $1 goesinteractive

Loading the interactive chart…

🌏Named in Asian annual reportsinteractive

Loading the interactive chart…

🔄Rotation against the market and its industry (RRG)interactive

Loading the interactive chart…

🔍Earnings qualityinteractive

Loading the interactive chart…

⚖️Fair value by methodinteractive

Loading the interactive chart…

🔭Outlook & guidanceinteractive

Loading the interactive chart…

📈Investments: gains and what it boughtinteractive

Loading the interactive chart…

🏭Its industry’s money flow (input-output)interactive

Loading the interactive chart…

About Cryo Cell International

Cryo-Cell International, Inc. (“the Company” or “Cryo-Cell”) was incorporated in Delaware on September 11, 1989 and is headquartered in Oldsmar, Florida. The Company is organized in three reportable segments: (1) cellular processing and cryogenic cellular storage, with a current focus on the collection and preservation of umbilical cord blood stem cells for family use (2) the manufacture of PrepaCyte CB units, the processing technology used to process umbilical cord blood stem cells and (3) cryogenic storage of umbilical cord blood stem cells for public use. Revenues for the cellular processing and cryogenic cellular storage represent sales of the umbilical cord blood stem cells program to customers and income from licensees selling the umbilical cord blood stem cells program to customers outside the United States.

In its own words, from its 10-Q, filed Oct 15, 2025.

Cryo Cell International against its Services-Misc Health & Allied Services, NEC peers

The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: 0% against the peers' median +5%. Operating margin: 28.0% against the peers' median 8.9%.

CompanyQuarterRevenueY/YOp. margin
CCEL Cryo Cell InternationalQ3 FY26$7.8M0%28.0%
DVA DavitaQ3 2026$3.6B+5%14.0%
AGL agilon healthQ3 2026$1.5B+6%1.6%
PGNY ProgynyQ3 2026$341M+9%10.3%
SHC Sotera HealthQ3 2026$325M+4%25.8%
VMD Viemed HealthcareQ3 2026$80.7M+12%8.6%
PARK Park Dental PartnersQ2 2026$66.2M+5%1.9%
MRAI MarpaiQ2 2026$4.2M-10%-82.4%
PFHO Pacific Health Care OrganizationQ3 2026$1.5M-5%8.9%

Source: Cryo Cell International 10-Q on SEC EDGAR · CIK 862692 · Services-Misc Health & Allied Services, NEC

13F: who owns CCEL and who is buying

Largest holders of CCEL (13F)Largest holders of CCEL (13F)SFI Advisors, LLC$694KVanguard Capital Management LLC$526KVanguard Group$519KMassMutual Private Wealth & Trust…$466KGeode Capital Management, LLC$148KVanguard Fiduciary Trust$74KFMR LLC$64KSusquehanna International Group, …$45KBlackRock$21KBarclays$20K
Funds' net buying of CCEL by quarter (13F)Funds' net buying of CCEL by quarter (13F)−$62024-09$235K2024-12$121K2025-03−$125K2025-06−$38K2025-09−$19K2025-12−$1.7M2026-03$72K2026-06
Value of shares 13F filers added minus the value they sold, each quarter (quarters with most filings in).

More on CCEL

History

Every quarter: Q3 FY26 results · Q2 FY26 results · Q1 FY26 results · Q4 FY25 results · Q3 FY25 results · Q2 FY25 results · Q1 FY25 results

Compare CCEL with

中文版：Cryo Cell International（CCEL）财报

Español · Français